Mayo Clinic Study Links Blood Biomarker to Future Cognitive Risk
A Mayo Clinic study found that blood levels of p-tau217, combined with age, sex and genetic risk, may help estimate the chance of mild cognitive impairment or dementia over five or 10 years. The researchers said testing is not currently recommended for people without cognitive symptoms.

A Mayo Clinic study found that a blood biomarker, combined with age, sex and genetic risk, may help estimate a cognitively healthy person’s chance of developing mild cognitive impairment or dementia over five or 10 years. The mayo study blood biomarker analysis linked higher p-tau217 levels and older age with greater risk.
Researchers analyzed 1,644 cognitively unimpaired participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer’s Disease Neuroimaging Initiative. Participants were ages 60 to 90 and had blood measurements, genetic testing and repeated cognitive assessments.
The team developed risk estimates using data from the Mayo Clinic Study of Aging, then checked the link between higher p-tau217 and cognitive decline in the second group.
For a 75-year-old woman who did not carry the APOE e4 genetic risk variant, the estimated five-year risk of mild cognitive impairment was 5% with a relatively low p-tau217 level and 16% with a higher level. Her estimated 10-year risk rose from 12% to 35%.
Age also changed the estimates. At the same high p-tau217 level, the estimated five-year risk of mild cognitive impairment ranged from 6% at age 65 to 37% at age 85.
“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” said Alicia Algeciras-Schimnich, a Mayo Clinic laboratory medicine and pathology researcher and the study’s first author.
The approach builds on earlier Mayo Clinic research that used brain scans to measure amyloid, a protein that accumulates in the brain in Alzheimer’s disease. The researchers said using a blood biomarker is less invasive and could be more scalable.
The findings could matter if therapies under study can prevent or delay cognitive decline before symptoms begin. Prevention trials AHEAD 3-45 and TRAILBLAZER-ALZ 3 are testing amyloid-targeting therapies and used blood biomarkers to help identify participants.
“If preventive therapies prove effective, those numbers could become very important in treatment decisions,” said Ronald Petersen, a Mayo Clinic neurologist and director of the Mayo Clinic Study of Aging.
The risk estimates were developed using one study population and need further evaluation in more diverse groups and with other p-tau217 blood tests. Alzheimer’s biomarker testing is not currently recommended for people without cognitive symptoms.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 2DUP Chairman Lord Morrow Loses Wife and Daughter Within Hours in NI

- 3Women With Autoimmune Diseases Wait About 4 Years for Diagnosis, Study Finds

- 4NASA’s Curiosity Rover Burst Open a Rock and Found Pure Sulfur

- 5Stock Market Today: Dow Futures Slip as Nasdaq Futures Climb Before Earnings

Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits















